CA2397723C - Brain, spinal and nerve injury treatment - Google Patents
Brain, spinal and nerve injury treatment Download PDFInfo
- Publication number
- CA2397723C CA2397723C CA2397723A CA2397723A CA2397723C CA 2397723 C CA2397723 C CA 2397723C CA 2397723 A CA2397723 A CA 2397723A CA 2397723 A CA2397723 A CA 2397723A CA 2397723 C CA2397723 C CA 2397723C
- Authority
- CA
- Canada
- Prior art keywords
- substance
- receptor antagonist
- formulation
- magnesium
- brain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
Abstract
A treatment for brain, spinal and nerve injury comprising use of a substance P
receptor antagonist optionally in combination with a magnesium compound. There is also provided a formulation for use in this treatment comprising a substance P receptor antagonist and a magnesium compound.
receptor antagonist optionally in combination with a magnesium compound. There is also provided a formulation for use in this treatment comprising a substance P receptor antagonist and a magnesium compound.
Description
riri r "BRAIN, SPINAL AND NERVE INJURY TREATMENT"
FIELD OF THE INVENTION
THIS INVENTION relates to a method of therapy of brain, spinal and nerve injury. There is also provided a formulation which is particularly useful in the method.
Injury to the brain results in the development of motor and cognitive deficits that contribute to the significant morbidity experienced by survivors of brain injury. Moreover, it is an l0 occurrence that has the highest incidence in younger members of society. Accordingly, injury to the brain is responsible for the greatest loss of productive life as compared to any other disease process. Despite this, there is no effective therapy to improve outcome after brain injury. We disclose the use of a method of therapy as a robust pharmacologic intervention for the treatment of brain injury. Use of this therapy significantly improves both motor and cognitive outcome in mild to severe experimental brain injury and has also been found to have beneficial effect also for the treatment of spinal cord and nerve injuries.
BACKGROUND OF THE INVENTION
It is well known that brain injury results in the development of neurologic deficits through two mechanisms. The first of these is known as primary mechanisms. These occur at the time of the injurious event and include mechanical processes such as laceration, tearing, stretching and compression of nerve fibres. Little can be done for this type of injury once it has occurred. The second mechanism is secondary injury, which includes biochemical and physiological processes, initiated by a primary injury but which manifest with time after the injury. It has been demonstrated that much of the morbidity after brain injury is associated with the development of this secondary injury. Given that the secondary injury develops from minutes to days after the primary event, there exists a window of opportunity to pharmacologically prevent this type of injury and significantly improve resultant outcome. However, the factors that make up secondary injury must first be identified and then "antifactors" developed to inhibit the injury process.
Our studies have concentrated on identifying secondary injury factors after brain injury and developing interventional therapies. One of the factors that we had previously identified'-4 as critical to determining outcome after injury was brain magnesium ion l0 concentration. This ion is a regulatory factor in a number of biochemical and physiological processes that are activated after brain injury. Indeed, a decrease in the magnesium ion concentration was observed to exacerbate the injury process while an increase in the concentration of magnesium ion was noted to attenuate the injury process and result in an improved outcome 5. The treatment of brain injury with magnesium has since been shown to be effective'~s~'° even when administered up to 24 hours after the primary event, and the success of the treatment in experimental animal studies has subsequently led to clinical trials in human brain injury.
Despite the attenuation of deficits after brain injury with magnesium administration, it was clear that there were still motor and cognitive deficits that persisted after the treatment. Our attention was particularly drawn to the fact that in younger animals, the accumulation of water in the brain (brain swelling) was still present and that this may present a significant risk factor. Indeed, in a recent clinical study", delayed brain swelling was responsible for 50% of all deaths recorded in young victims of brain injury.
STATEMENT OF INVENTION
It therefore is an object of the invention to provide a method of therapy in relation to brain injury and a formulation for use in the method.
FIELD OF THE INVENTION
THIS INVENTION relates to a method of therapy of brain, spinal and nerve injury. There is also provided a formulation which is particularly useful in the method.
Injury to the brain results in the development of motor and cognitive deficits that contribute to the significant morbidity experienced by survivors of brain injury. Moreover, it is an l0 occurrence that has the highest incidence in younger members of society. Accordingly, injury to the brain is responsible for the greatest loss of productive life as compared to any other disease process. Despite this, there is no effective therapy to improve outcome after brain injury. We disclose the use of a method of therapy as a robust pharmacologic intervention for the treatment of brain injury. Use of this therapy significantly improves both motor and cognitive outcome in mild to severe experimental brain injury and has also been found to have beneficial effect also for the treatment of spinal cord and nerve injuries.
BACKGROUND OF THE INVENTION
It is well known that brain injury results in the development of neurologic deficits through two mechanisms. The first of these is known as primary mechanisms. These occur at the time of the injurious event and include mechanical processes such as laceration, tearing, stretching and compression of nerve fibres. Little can be done for this type of injury once it has occurred. The second mechanism is secondary injury, which includes biochemical and physiological processes, initiated by a primary injury but which manifest with time after the injury. It has been demonstrated that much of the morbidity after brain injury is associated with the development of this secondary injury. Given that the secondary injury develops from minutes to days after the primary event, there exists a window of opportunity to pharmacologically prevent this type of injury and significantly improve resultant outcome. However, the factors that make up secondary injury must first be identified and then "antifactors" developed to inhibit the injury process.
Our studies have concentrated on identifying secondary injury factors after brain injury and developing interventional therapies. One of the factors that we had previously identified'-4 as critical to determining outcome after injury was brain magnesium ion l0 concentration. This ion is a regulatory factor in a number of biochemical and physiological processes that are activated after brain injury. Indeed, a decrease in the magnesium ion concentration was observed to exacerbate the injury process while an increase in the concentration of magnesium ion was noted to attenuate the injury process and result in an improved outcome 5. The treatment of brain injury with magnesium has since been shown to be effective'~s~'° even when administered up to 24 hours after the primary event, and the success of the treatment in experimental animal studies has subsequently led to clinical trials in human brain injury.
Despite the attenuation of deficits after brain injury with magnesium administration, it was clear that there were still motor and cognitive deficits that persisted after the treatment. Our attention was particularly drawn to the fact that in younger animals, the accumulation of water in the brain (brain swelling) was still present and that this may present a significant risk factor. Indeed, in a recent clinical study", delayed brain swelling was responsible for 50% of all deaths recorded in young victims of brain injury.
STATEMENT OF INVENTION
It therefore is an object of the invention to provide a method of therapy in relation to brain injury and a formulation for use in the method.
The formulation in one aspect of the invention comprises a substance P receptor antagonist and a magnesium compound.
The method of the invention includes the step of administration of the formulation to the patient suffering from brain injury. Alternatively each of the components of the formulation are administered separately or separated by a time delay that does not affect the effectiveness of the therapy, e.g. 1-30 minutes.
Substance P is an excitatory neurotransmitter and has a role in pain transmission and is a peptide having the structure l0 RPKPEEFFGLM-NH2. It is from the hypothalamus, CNS and intestine and increases smooth muscle contraction of the G 1 tract.
It is known that substance P binds to a number of receptors inclusive of the NK1 receptor (i.e. neurokinin 1 receptor), the NK2 receptor and the NK3 receptor. These receptors are believed to have a role in blood travelling to the brain.
Therefore a substance P antagonist is a substance that inhibits binding of substance P to any one of the receptors referred to above. A list of suitable substance P antagonists is referred to in Tables 1, 2 and 3 attached herewith.
Reference may also be made to NK1 receptor antagonists as described in US Patent 5990125 which are incorporated herein by reference as constituting substance P
antagonists that may be utilized in the formulation of the method of the invention. This has specific reference to compounds of structures la, Ib, Ic, Id, 1e, X, XVI, XVII, XVIII, XIX, XX and XXI, as well as other antagonists comprising quinuclidine, piperidine ethylene diamine, pyrrolidine and azabornane derivatives and related compounds that exhibit activity as substance P receptor antagonists as described in column 33 of the US Patent 5990125.
Such receptor antagonists may be employed having regard to the dosages referred to in column 34 of US Patent 4990125 and in various forms of administration i.e. alone or with various pharmaceutically acceptable carriers or diluents by oral administration or parental administration as referred in column 34 of US Patent 5990125.
The activity of various substances as _ substance P
receptor antagonists for use in the invention may also be determined by the assays referred to in columns 35-36 of US Patent 5990125.
Reference also may be made to substance P receptor antagonists described in US Patent 5977104 including the various dosage forms and dosages referred to in this reference which is also totally incorporated herein by reference.
Reference also may be made to US Patent 4481139 which describes various peptide antagonists, which is also totally incorporated herein by reference.
It will also be understood that the term "Substance P" as used herein may also include within its scope various truncated forms or analogues as described in US Patent 4481139, which is totally incorporated herein by reference.
Reference also may be made to US Patent 4985896 which refers to various piperdine and morpholine derivatives for use as substance P antagonists for use in the present invention or piperazino derivatives as described in US Patent 5981520. Each of these references are totally incorporated herein by reference.
Reference also may be made to piperidinyl compounds as NK1 or NK2 antagonists for use in the invention referred to in US
Patent 5998444 which is also totally incorporated herein by reference.
It will also be appreciated that tachykinin antagonists referred to in US Patent 4981744 may also be used as substance P
antagonists in the invention and thus, this reference is also totally incorporated herein.
Reference may also be made to EP-A-1035115 which is totally incorporated herein by reference, which refers to N-benzyl-4-tolylnicotinamides and related compounds as NK1 receptor antagonists for use in the invention.
The method of the invention includes the step of administration of the formulation to the patient suffering from brain injury. Alternatively each of the components of the formulation are administered separately or separated by a time delay that does not affect the effectiveness of the therapy, e.g. 1-30 minutes.
Substance P is an excitatory neurotransmitter and has a role in pain transmission and is a peptide having the structure l0 RPKPEEFFGLM-NH2. It is from the hypothalamus, CNS and intestine and increases smooth muscle contraction of the G 1 tract.
It is known that substance P binds to a number of receptors inclusive of the NK1 receptor (i.e. neurokinin 1 receptor), the NK2 receptor and the NK3 receptor. These receptors are believed to have a role in blood travelling to the brain.
Therefore a substance P antagonist is a substance that inhibits binding of substance P to any one of the receptors referred to above. A list of suitable substance P antagonists is referred to in Tables 1, 2 and 3 attached herewith.
Reference may also be made to NK1 receptor antagonists as described in US Patent 5990125 which are incorporated herein by reference as constituting substance P
antagonists that may be utilized in the formulation of the method of the invention. This has specific reference to compounds of structures la, Ib, Ic, Id, 1e, X, XVI, XVII, XVIII, XIX, XX and XXI, as well as other antagonists comprising quinuclidine, piperidine ethylene diamine, pyrrolidine and azabornane derivatives and related compounds that exhibit activity as substance P receptor antagonists as described in column 33 of the US Patent 5990125.
Such receptor antagonists may be employed having regard to the dosages referred to in column 34 of US Patent 4990125 and in various forms of administration i.e. alone or with various pharmaceutically acceptable carriers or diluents by oral administration or parental administration as referred in column 34 of US Patent 5990125.
The activity of various substances as _ substance P
receptor antagonists for use in the invention may also be determined by the assays referred to in columns 35-36 of US Patent 5990125.
Reference also may be made to substance P receptor antagonists described in US Patent 5977104 including the various dosage forms and dosages referred to in this reference which is also totally incorporated herein by reference.
Reference also may be made to US Patent 4481139 which describes various peptide antagonists, which is also totally incorporated herein by reference.
It will also be understood that the term "Substance P" as used herein may also include within its scope various truncated forms or analogues as described in US Patent 4481139, which is totally incorporated herein by reference.
Reference also may be made to US Patent 4985896 which refers to various piperdine and morpholine derivatives for use as substance P antagonists for use in the present invention or piperazino derivatives as described in US Patent 5981520. Each of these references are totally incorporated herein by reference.
Reference also may be made to piperidinyl compounds as NK1 or NK2 antagonists for use in the invention referred to in US
Patent 5998444 which is also totally incorporated herein by reference.
It will also be appreciated that tachykinin antagonists referred to in US Patent 4981744 may also be used as substance P
antagonists in the invention and thus, this reference is also totally incorporated herein.
Reference may also be made to EP-A-1035115 which is totally incorporated herein by reference, which refers to N-benzyl-4-tolylnicotinamides and related compounds as NK1 receptor antagonists for use in the invention.
5 Reference may be made to International Publication WO
0050398 which is totally incorporated herein by reference, which refers to various phenyl and pyridinyl derivatives as NK1 receptor antagonists for use in the invention.
Reference is also made to International Publications WO
l0 0050401, WO 0053572, WO 0073278 and WO 0073279, which refer to 3-phenylpyridines, biphenyl derivatives, 5-phenyl-pyrimidine derivatives and 4-phenyl-pyrimidine derivatives respectively which specifications are also totally incorporated herein by reference. These specifications refer to NK1 receptor antagonists for use in the present invention.
Reference also may be made to the 1998 Sigma Catalogue and more particularly pages 1194-1997 which describe modifications of substance P or substance P fragments, which may be used as substance P antagonists, for use in the invention. This publication is also totally incorporated herein by reference.
In relation to the magnesium compound, this may comprise any suitable source of magnesium ion such as magnesium chloride, magnesium sulphate, magnesium oxalate, magnesium gluconate or other non toxic magnesium salt.
The pharmaceutical preparations in accordance with this invention can in addition also contain preservatives, solubilizers, sabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances. Thus the term "comprising"
used in the specification should be interpreted in this context. The dosage can vary within wide limits and can, of course, be fitted to the individual requirements in each particular case. In general, a dosage of 1 to 20000mg per patient, preferably10 to 5000mg and more preferably 50 to 2000mg of the substance P receptor antagonist should be appropriate.
In relation to the development of the inventive concept, it was established by the present inventors that one reason for acute water accumulation in the brain after injury was the result of vasogenic oedema formation. This is caused by an increased permeability of the blood brain barrier thus permitting vascular proteins and water to enter the extracellular space in the brain and cause swelling. Few studies have examined how this increased blood brain barrier permeability contributes to the development of neurological deficits after injury, and no studies have investigated whether inhibition of brain swelling improves outcome. Studies of migraine'z~'3 have suggested that the blood brain barrier becomes permeable to vascular components because of substance P. We therefore hypothesised that administration of a substance P receptor antagonist may prevent brain swelling and the development of delayed neurologic deficits after injury. This hypothesis was a result of our discovery referred to above, that water accumulated in the brain as a result of vasogenic oedema formation.
EXPERIMENTAL
A number of commercially synthesised substance P
receptor antagonists are currently available from standard scientific chemical suppliers, as is apparent from Tables 1, 2 and 3. We chose to use the compound N-acetyl-L-tryptophan based on its low lipid solubility that limits its ability to naturally cross the blood brain barrier and the fact that it is relatively inexpensive. Administration of N-acetyl-L-tryptophan at an intravenous dose of 246mg/kg (saline vehicle? given at 30 minutes after brain injury resulted in a significant improvement of cognitive outcome in brain injured animals as assessed by the Barnes Circular Maze. Similarly, there was a significant improvement in motor outcome of animals as assessed by the rotarod test. These improvements in outcome were apparent at 24 hours after brain injury and persisted for the 14 day assessment period. Control (vehicle tested) animals has significantly worse neurologic outcome than treated animals at all time points tested.
Animals treated with N-acetyl-L-tryptophan had a significant reduction in brain water accumulation at 24 hours after l0 injury as compared to vehicle treated controls. This was consistent with the observation that N-acetyl-L-tryptophan reduced brain penetration of Evans blue at 5 hours after injury, the time associated with maximum blood brain barrier permeability after brain injury.
Thus N-acetyl-L-tryptophan administered at 30 minutes after brain injury reduced blood brain barrier permeability and reduced vasogenic oedema formation. The fact that these effects were noted with a non-permeable formulation of the NK1 antagonist suggests that the effects were largely mediated by vascular receptors and not dependent upon central receptors.
Administration of N-acetyl-L-tryptophan at 24.6 mg/kg also significantly improved cognitive outcome of brain injured animals.
However, the drug had less of a beneficial effect on motor outcome.
Moreover, because there was always some residual cognitive and motor deficits noted in all treated animals, the beneficial effects of treatment with the NK1 antagonist were less apparent when injury of mild severity was induced as opposed to injury of a sever nature.
This is a major limitation given that mild head injury has the greatest incidence in brain injury patients.
COMBINATION MAGNESIUM AND N-ACETYL-L-TRYPTOPHAN
The most common form of brain injury is mild head injury. Guidelines to be introduced next year (2000) by the World Federation of Neurological Surgeons will recommend that all cases of minor head injury with any complications such as vomiting, nausea, loss of consciousness or amnesia MUST present to a hospital. This will place considerable pressure on the health system to adequately treat these individuals such that secondary injury does not develop any further. Currently, there is no such therapy.
Our results with N-acetyl-L-tryptophan suggest that this compound closes the blood brain barrier after head injury and reduces brain swelling. This is extremely important in young victims of head l0 injury who are particularly vulnerable to delayed brain swelling.
Furthermore, our results with magnesium therapy suggest that magnesium treatment is effective at reducing neurologic deficits not necessarily associated with increased blood brain permeability. We therefore propose that a combination of a substance P antagonist with a magnesium compound or salt will be a particularly effective therapy for the treatment of brain injury irrespective of severity.
Combination administration of 246 mg/kg N-acetyl-L-tryptophan plus 30 mg/kg magnesium sulphate (intravenously) resulted in a profound attenuation of both motor and cognitive deficits that was significantly greater than obtained with either drug in isolation (FIG. 1 and FIG. 2).
Each of the compounds in the combination formulation has a number of properties that make it particularly attractive for use in brain injury.
Substance P (SP) antagonists have been shown to rapidly improve mood by antagonising substance P induced anxiety.
Thus they are effective in treating post-injury depression. From the work described above, it is apparent that SP antagonists reduce blood brain barrier permeability and inhibit the formation of vasogenic oedema and post-injury brain swelling. The antagonists also have been shown to inhibit pain. There are high numbers of substance P
0050398 which is totally incorporated herein by reference, which refers to various phenyl and pyridinyl derivatives as NK1 receptor antagonists for use in the invention.
Reference is also made to International Publications WO
l0 0050401, WO 0053572, WO 0073278 and WO 0073279, which refer to 3-phenylpyridines, biphenyl derivatives, 5-phenyl-pyrimidine derivatives and 4-phenyl-pyrimidine derivatives respectively which specifications are also totally incorporated herein by reference. These specifications refer to NK1 receptor antagonists for use in the present invention.
Reference also may be made to the 1998 Sigma Catalogue and more particularly pages 1194-1997 which describe modifications of substance P or substance P fragments, which may be used as substance P antagonists, for use in the invention. This publication is also totally incorporated herein by reference.
In relation to the magnesium compound, this may comprise any suitable source of magnesium ion such as magnesium chloride, magnesium sulphate, magnesium oxalate, magnesium gluconate or other non toxic magnesium salt.
The pharmaceutical preparations in accordance with this invention can in addition also contain preservatives, solubilizers, sabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances. Thus the term "comprising"
used in the specification should be interpreted in this context. The dosage can vary within wide limits and can, of course, be fitted to the individual requirements in each particular case. In general, a dosage of 1 to 20000mg per patient, preferably10 to 5000mg and more preferably 50 to 2000mg of the substance P receptor antagonist should be appropriate.
In relation to the development of the inventive concept, it was established by the present inventors that one reason for acute water accumulation in the brain after injury was the result of vasogenic oedema formation. This is caused by an increased permeability of the blood brain barrier thus permitting vascular proteins and water to enter the extracellular space in the brain and cause swelling. Few studies have examined how this increased blood brain barrier permeability contributes to the development of neurological deficits after injury, and no studies have investigated whether inhibition of brain swelling improves outcome. Studies of migraine'z~'3 have suggested that the blood brain barrier becomes permeable to vascular components because of substance P. We therefore hypothesised that administration of a substance P receptor antagonist may prevent brain swelling and the development of delayed neurologic deficits after injury. This hypothesis was a result of our discovery referred to above, that water accumulated in the brain as a result of vasogenic oedema formation.
EXPERIMENTAL
A number of commercially synthesised substance P
receptor antagonists are currently available from standard scientific chemical suppliers, as is apparent from Tables 1, 2 and 3. We chose to use the compound N-acetyl-L-tryptophan based on its low lipid solubility that limits its ability to naturally cross the blood brain barrier and the fact that it is relatively inexpensive. Administration of N-acetyl-L-tryptophan at an intravenous dose of 246mg/kg (saline vehicle? given at 30 minutes after brain injury resulted in a significant improvement of cognitive outcome in brain injured animals as assessed by the Barnes Circular Maze. Similarly, there was a significant improvement in motor outcome of animals as assessed by the rotarod test. These improvements in outcome were apparent at 24 hours after brain injury and persisted for the 14 day assessment period. Control (vehicle tested) animals has significantly worse neurologic outcome than treated animals at all time points tested.
Animals treated with N-acetyl-L-tryptophan had a significant reduction in brain water accumulation at 24 hours after l0 injury as compared to vehicle treated controls. This was consistent with the observation that N-acetyl-L-tryptophan reduced brain penetration of Evans blue at 5 hours after injury, the time associated with maximum blood brain barrier permeability after brain injury.
Thus N-acetyl-L-tryptophan administered at 30 minutes after brain injury reduced blood brain barrier permeability and reduced vasogenic oedema formation. The fact that these effects were noted with a non-permeable formulation of the NK1 antagonist suggests that the effects were largely mediated by vascular receptors and not dependent upon central receptors.
Administration of N-acetyl-L-tryptophan at 24.6 mg/kg also significantly improved cognitive outcome of brain injured animals.
However, the drug had less of a beneficial effect on motor outcome.
Moreover, because there was always some residual cognitive and motor deficits noted in all treated animals, the beneficial effects of treatment with the NK1 antagonist were less apparent when injury of mild severity was induced as opposed to injury of a sever nature.
This is a major limitation given that mild head injury has the greatest incidence in brain injury patients.
COMBINATION MAGNESIUM AND N-ACETYL-L-TRYPTOPHAN
The most common form of brain injury is mild head injury. Guidelines to be introduced next year (2000) by the World Federation of Neurological Surgeons will recommend that all cases of minor head injury with any complications such as vomiting, nausea, loss of consciousness or amnesia MUST present to a hospital. This will place considerable pressure on the health system to adequately treat these individuals such that secondary injury does not develop any further. Currently, there is no such therapy.
Our results with N-acetyl-L-tryptophan suggest that this compound closes the blood brain barrier after head injury and reduces brain swelling. This is extremely important in young victims of head l0 injury who are particularly vulnerable to delayed brain swelling.
Furthermore, our results with magnesium therapy suggest that magnesium treatment is effective at reducing neurologic deficits not necessarily associated with increased blood brain permeability. We therefore propose that a combination of a substance P antagonist with a magnesium compound or salt will be a particularly effective therapy for the treatment of brain injury irrespective of severity.
Combination administration of 246 mg/kg N-acetyl-L-tryptophan plus 30 mg/kg magnesium sulphate (intravenously) resulted in a profound attenuation of both motor and cognitive deficits that was significantly greater than obtained with either drug in isolation (FIG. 1 and FIG. 2).
Each of the compounds in the combination formulation has a number of properties that make it particularly attractive for use in brain injury.
Substance P (SP) antagonists have been shown to rapidly improve mood by antagonising substance P induced anxiety.
Thus they are effective in treating post-injury depression. From the work described above, it is apparent that SP antagonists reduce blood brain barrier permeability and inhibit the formation of vasogenic oedema and post-injury brain swelling. The antagonists also have been shown to inhibit pain. There are high numbers of substance P
receptors in the hippocampus and striatum, those parts of the brain that are known to be associated with learning and memory. Inhibition of binding with SP antagonists may thus prevent substance P induced deficits in learning and memory. Our evidence presented above suggests that this may be the case. This has never been shown previously. Indeed, there has been no literature on the role of substance P, or any neuropeptides, in brain injury.
Magnesium affects over 300 cellular enzymes. It is not surprising, therefore, that magnesium has numerous targets at which l0 it may improve outcome. These include, amongst others, blocking glutamate induced excitotoxicity, improving membrane stability and reducing the production of reactive oxygen species, improving energy status, inhibiting calcium channels, reducing neurotransmitter release, inhibiting mitochondria) transition pore opening, and inhibiting apoptosis. Notably, it also blocks glutamate induced release of substance P. Physiologically, magnesium has been shown'4-" to improve cerebral blood flow, reduces cerebral vasospasms, and reduces vascular ceramide and prostaglandin production.
The combined use of magnesium and the substance P
antagonist results in greater protection against neural injury than either drug used alone.
We have previously shown that magnesium has a beneficial effect in trauma when administered at intravenous doses ranging from 16 to 60 mg/kg. When administered as an intramuscular injection, the effective dose varies form 45 to 90 mg/kg. The target is to increase free magnesium concentration in the blood to approximately 1 .OmM, which is double the normal blood free magnesium concentration. Beneficial results are observed irrespective of the magnesium salt used.
Our studies with the substance P antagonist has demonstrated that the effective i.v. dose varies from 24.6 mg/kg to 240.6 mg/kg or higher, with the higher doses having a greater beneficial effect on motor outcome. Moreover, these doses pertain to antagonists that have low lipid solubility and thus limited blood brain barrier permeability. A highly lipid soluble formulation should exact 5 the same beneficial actions, however, there may be centrally mediated side-effect that may be inappropriate.
When used in combination, the formulation may vary in the range described for the individual components. We have achieved excellent results using the maximum i.v. doses described for l0 the individual components.
The combination magnesium/SP antagonists is expected to be useful in the following conditions:
~ As a "first-aid" prophylactic treatment following traumatic brain injury ~ As a "first-aid" prophylactic treatment following minor head injuries, including concussion ~ As a therapy following non-traumatic brain injuries, including stroke, hypoxia and any form of brain injury where oedema is implicated ~ As a maintenance therapy following brain injury REFERENCES
1. Vink R, Mclntosh TK, Demediuk P, Weiner MW, Faden AI:
Decline in intracellular free magnesium concentration is associated with irreversible tissue injury following brain trauma.
J Biol Chem 263: 757-761, 1988 2. Vink R, Heath DL, Mclntosh TK: Acute and prolonged alterations in brain free magnesium following fluid percussion induced brain trauma in rats. J Nurochem 66:2477-2483, 3. Heath DL, Vink R: Brain intracellular free magnesium concentration declines following impact-acceleration induced brain injury in rats. Neurosci Res Commun 18: 163-168, 1996 4. Heath DL, Vink R: Traumatic brain axonal injury produces sustained decline in intracellular free magnesium-concentration.
Brain Research 738: 150-153, 1996 5. Mclntosh TK, Faden AI, Yamakami I, Vink R: Magnesium deficiency exacerbates and pretreatment improves outcome following traumatic brain injury in rats: 3'P magnetic resonance l0 spectroscopy and behavioural studies. J Neurotrauma 5: 17-31, 1988 6. Vink R, Mclntosh TK: Pharmacological and physiological effects of magnesium on experimental traumatic brain injury.
Magnesium Res 3: 163-169, 1990 7. Heath DL, Vink R: Magnesium sulphate improves neurologic outcome following sever closed head injury in rats.
Neuroscience Letters 228: 175-178, 1997 8. Heath DL, Vink R: Neuroprotective effects of MgS04 and MgC12 in closed head injury: a comparative phosphorus NMR
study. J Neurotrauma 15: 183-189, 1998 9. Heath DL, Vink R: Delayed therapy with magnesium up to 24 hours following traumatic brain injury improves motor outcome.
J Neurosurg 90: 504-509, 1999 10. Heath DL, Vink R: Optimisation of magnesium therapy following sever diffuse axonal brain injury in rats. J Pharmacol Exp Ther 288: 131 1-1316, 1999 11. Feickert HG, Drommer S, Heyer R: Severe head injury in children: impact of risk factors. J Trauma 47: 33-38, 12. Moskowitz MA: The neurobiology of vascular head pain.
Ann Neurol16: 157-168, 1984 13. Ferrari MD: Migraine. Lancet 351: 1043-1052, 1998 14. Altura BT, Altura BM: The role of magnesium in etiology of strokes and cerebrovasospasm. Magnesium 1 : 277-291, 1982 15. Farago M, Szabo C, Dora E, Horvath I, Kovach AGB:
Contractile and endothelium-dependant dilatory_ responses of cerebral arteries at various extracellular magnesium concentration. J Cereb Blood Flow Metab 1 1 : 161-1 64, 1991 16. Kemp PA, Gardiner SM, March JE, Rubin PC, Bennett T:Assessment of the effects of endothelia-1 and magnesium l0 sulphate on regional blood flows in conscious rats, by the colour microsphere reference technique. Br J Pharmacol 126:
621-626, 1999 17. Morril MA, Gupta RI<, Kostellow AB, Gy M, Zhang A, Altura BT, Altura BM: Mg2 + modulates membrane sphingolipid and lipid second messenger levels in vascular smooth muscle cells.
FEBS Lett 167-171, 1998 ~
E
c4 C
-o t n.
L
L U
n N t N
l- ~U '-' cB i N
C (n O n L , N ~
o ~ ~_ ~ ~ u~
J U ~ s O
U _ , C p Q N
~J1O
N p L
M ~ N L ., L ..-1 ~ N 'p v ~ ' ~ COp >, C 7, '~ ~U ~ N
w-. C L O r C o ~ y ~ C u) E
C _ 0 N N Z ~ Q 0 o B , .=, N ' C N O ~ = ~' O N >, C N
T
O O O O .t..C ~ .C N ~ , Q. U p fl. .-. ~ '~ C
'Q v ~ Q ~ a ~ a~ E a7 ~ 'C N
'_d'fCO 7, Z, C1 r T C Q r d i N O
N C O C a O
, p , O T CL r ~ p , ~ 7 _ x O r ~ Q. O ~' O
N ' L N N ~ ~ C v L ~ O J Q ~ _ ~ N v ~ ~' i~
O E p 7, v '; ~E ~ ' N ~ f~
E C - N ~ Z
C - O- CC O _ >, c0 r iv ~ >' M
a c ~ >, ~ ~ C ~. X ~ :.
L >' p N p u7 >, .C O T
Z C C ~ C E t N ~ O = Q O
X N O T ~ O Q p ~ ~. ~ t ~ O. ~, c%~' o r s 7, N fn t N O ~ >, ~ fl.z N N p 7, ...~ L ~ - L p ~ L ~, X
O N O .-.C N ~ H _O, d N
N O .- O t C ~ O ~ ' ~ u) O Z ~ ~ C ~
_c~0 '''~ O ~ ~ N ~ N
E ~, ' O ' tf7' O ~ O p >, C N
7, , >' J ~ L C ~ p Z C r p X E O 'p N E E
7,O ..~~.p L ~ ~ ~ ~ ->~~O
O D ~ p "'.'~ S O
N ~' ' ~-'p U i ~ ~.;~ ~ ~, O
~n E O X v p ~ ~ ~ M C C
s O ~ ~ N cC ~ N cp Z ~! C N ,_..,j, N i ~ Q i U w , r ~ ~ ~ x ~ Z ~ L Z d ~ L , ~ O Q' H M
T 'Ov N .Q M C ~ O O
M yr _>,Q' O _cC n rj ~ v O p ' ~
N M ~ N ~ Q ~ "'' ~ ~
C ' N V ~ -~ C t~ _~O_ J M
~ ~ 'O ~ 'O U ~ r V ~ U ~ M ' CC C ~ Q -C 7, ~
M ~ ~ (n N O O N ~ N (!~iv ~ ~ M ~ N ~ M d a U a N U
iv N ' ~ N N
N fn ~ ~ d Q ~
M ~ ~ M r Z ~r ~
C
Q
O
O
O U M tn~' N O r U t0 N ~hO~ I~ ~ r M O I~ O O
O 0 ct LIJ t~ ~ M ~ ~0 p r N ~ ~ ~ r O (O O
O N r O
d O O o0 N N a0 O M N M N
U U an ~ J
U U U I~tC~ C7 C9 C'~Z J J J J
i4 , z ,"
' o _ ~
s >, J
T
O ~ ~ V :Q >, c c _(p ~
, COU ~, N U ca r~ ~ n , C r T O I~
Z - N
D O 7, O ~ C r t fl.~ Q ~ L N
r n = 1 N
O O ~ p ~ , a . (D
.C ~ U ~ ~ p ~ O r , CO U E ~ ~ ~ ~ tn _O et _~ , i , O O U_ r , n 7, ~ ~ C 'O~O
m .
->, N , ' _ L ~ V N
O O .
T ~, Z .C ~ ' ' .C r C ~ c4 Q N
~ = ~ T O O ~, ~
j, ~
7 t _ ~ ~,O M r te r ~- c ... ~ .ca _>, ..
o E J E _ E z ~ O ~ O T p -p 7 ~' L =
, , c M
~ > O t N
T , ~ ~ , O CC
n ' ~ n c M c~7T t ~ C -, ~ M
. n 7, _, n _I n O C ~ ~ M
O_ ~
C .C O O p O O N
C C ~ ~ O ~ n p ~ N
O t0 ~_ C 7, ~ ' C
X Z ~ = U ~ N J O ~ >, OJ r d r 0 ~' p N ' .-, ~ _ ~! = CE
p_ o M w .C ~ ~
-on ~ ' >
, N
', X , T >, C M
U
_ r O , p L ~, ~ ~ ~ ~ ~ "
7 ' ~
c ~ c o X a a c y o 0 a N .E j ~ + ~ N ~- r O J N
. o r ' r , , ~ + E W ~ ~ 1 U n c r d , + 1 c , 'L
t a C .
r L C C ~ M n Q (n CU
7, ~ ' N ~ p >, N N
~' N ~ ~
c N ~ N ~, ~, ~ ca ~
a V ~ ~' , . 1 ~~ V N O
.
o E M ~, c ~. I
~ o s U c J >, o ce c = t ~ ~ ~ O = O ~ ' C O N
Q 7 ~
, n c ca . z Q ~ N
. C , cn 'c . r C 7 ' ~ z C >' , i V O >, p ~, n p x .g o = o >' o c~ o t I~ p >, ~ ~
~ ' ,n p * .c .J .c M o . ~ n n ' , O w-.~ .....i ~ n .. L = Q ~ ~
~ .M. M
r s_ p M N O , t- ..~ H ~
N~. L N ~,M
"
~ X O , ~ ~ M
~ N C ~ ~ O ~ ~ O O
~ * _ N ~ ~ '~~ C p_ ~
o ' ~ '-' ~ I co ca ~n p_' O v~ ~ ~ v ~ p N ~ N C U - n ~
~, CO , ~, C4 t r r =
M O N ~ a7 ' ~"~ n N ~ CV Z ~ "
~ -, ' .~ U .,..U Z i ~ m ~ C r , c 1 N N cU r t c ~ , N N p * >
, , ,_ N ~ s ~ ~ ~ - , , f , U -, ., ~ ~ n ~
.
n N N N , ~ ~ ~ ~ ~ p > C ~ O
c , N s Q"
Z ~ . c , N
a . O U
_ Z N Z ' d _ N O N nJ '=
~ N ~ ~
O s ~ t U
>, - 't?
: ai ~ ai ~ ~ U z ~ n ~ U , s- n _ N >, :o ~ :a - c O a a~'~ N ~ o , ~ n o C N ~ >, ~ ~ O N i. t ' _ Z , ' ~ O
Cvj Z Q n ' C.rj~ V T N
n ~ n ~-' ~-'' ~ U O ~ ~ 0 ~ ~' 'D ~
-' s o C7,N U ~ U e~ OCS i' v ~ iv O a ;o ~ Nr C Q ~ ~ C ~ . l (n s , ~o o N
- M C , C N N ~ N J, . c0 n ~ CC a M fC M ' ~ " L , p ~ ~
O ~ N ~ N t ~ '~ Q' OC N U ~' t ~ .r Q, c Z ~ ~ ~ N ~ . O
O ~ U
p I~'ct, J N N ~
~
V fl r n C N p ~ U r ~ mN
. . _ ~ r ' f- ~ ~ O~ ~ ' ' o -o d a ~ %~ a. ~ ~ ~ m ca T z - ~ t~
o Z
~
J E ~ ~ ~ N M ~ Q ~ v H D J ~ 'O
U 'a N
M
O O O
r O O ~ O '-~~~ M
O N ~ ~ r O ~ O -p O N r o O u7O 'Q 'O M N
p O O O r ~ ~ ~ ~ r ~ :. :~. ~ V~ (O
p M M M Z , ~ ~ ~ ~ T COO r Z Z
~
t0 _ _ < ~ ~ ~ ~ Y p 'n a ~ n n n J J J J ~ ~ d x , L
N
U
m .
o E
s ~ E ca , N N >, .fl E E c L
N Z _ U
, O
'O
r !~ n 'ct E
, ~ ~ L
~ ~ O
c ~ c , .o 47 , C
-p ~ c .L
~1 ~L
.a n 'a .c .
... _~- >, n c >' c :o c c a~ o .c o ' ~ ~ a~
n 'n L ~r :~ o .~ , o t >, Q ~_ M
U S O E 7, d 'd' O s O
~, ~
M ~, N
N O
N C C U 7, O
- ' ' ~. O
. O I N t . ~ 'C N Z U
C
_ f t O C n , N ~' n -O _ >' N
fl-n ~ E N
ca C ' Q ...C = Q E 7, C z L = C N
~
N ~ N O n Z O O C
, '_"
O .C z O , t ~ N
U O p O N N Q. ,~
M
d U m ~ N
' O d U N T
~
O 7 ~ 'p vp ~ ' - ~ ~n E
o Z caE ri o N
O M , " a> Q c% y 0 ~ ~ ~ a cQ: ;
~ N
!
, N Q, p , j ~ N
N >, _ CO T Q N ~ C i N
~.
a N L c 7, O ~
, = ~, O fl. H n ' O.~
C , ~... r N ~ ~ ~ N ~ d , 7, , >, Z N-Q ~ ~ ~ r ~ = t U rM
o r !0 , z M ~ ~ cC ~
~
t H Q , Q ~ U
.
_, , ~ N v ~ U 47 Z
V O O ~ !3 ~ > , L
C7 ~
tn , , ~ ' ~ d ; O ~ ~ z O
Z o o c~ V
U U - ~ ~
Q L ~ . L Q L ~ ~ , ~
.
V ~ V U ~ d V M = a r Q Q
d L d 'a Q O Q
O
I~ (~ r M
U iv c ~ ~ ~ U iv ~
o o c LLI t,1O O op ~ N v N ~ N a0 Q N
~ r ~ ~t J ' ~r N o ~ W m N ~
r ~ c ~ ~ M r ~ o ~ 00 Y
o O
V fn J ~ fn C9 ~ Z C) fn o' Q'cn J Z
I-Z
Magnesium affects over 300 cellular enzymes. It is not surprising, therefore, that magnesium has numerous targets at which l0 it may improve outcome. These include, amongst others, blocking glutamate induced excitotoxicity, improving membrane stability and reducing the production of reactive oxygen species, improving energy status, inhibiting calcium channels, reducing neurotransmitter release, inhibiting mitochondria) transition pore opening, and inhibiting apoptosis. Notably, it also blocks glutamate induced release of substance P. Physiologically, magnesium has been shown'4-" to improve cerebral blood flow, reduces cerebral vasospasms, and reduces vascular ceramide and prostaglandin production.
The combined use of magnesium and the substance P
antagonist results in greater protection against neural injury than either drug used alone.
We have previously shown that magnesium has a beneficial effect in trauma when administered at intravenous doses ranging from 16 to 60 mg/kg. When administered as an intramuscular injection, the effective dose varies form 45 to 90 mg/kg. The target is to increase free magnesium concentration in the blood to approximately 1 .OmM, which is double the normal blood free magnesium concentration. Beneficial results are observed irrespective of the magnesium salt used.
Our studies with the substance P antagonist has demonstrated that the effective i.v. dose varies from 24.6 mg/kg to 240.6 mg/kg or higher, with the higher doses having a greater beneficial effect on motor outcome. Moreover, these doses pertain to antagonists that have low lipid solubility and thus limited blood brain barrier permeability. A highly lipid soluble formulation should exact 5 the same beneficial actions, however, there may be centrally mediated side-effect that may be inappropriate.
When used in combination, the formulation may vary in the range described for the individual components. We have achieved excellent results using the maximum i.v. doses described for l0 the individual components.
The combination magnesium/SP antagonists is expected to be useful in the following conditions:
~ As a "first-aid" prophylactic treatment following traumatic brain injury ~ As a "first-aid" prophylactic treatment following minor head injuries, including concussion ~ As a therapy following non-traumatic brain injuries, including stroke, hypoxia and any form of brain injury where oedema is implicated ~ As a maintenance therapy following brain injury REFERENCES
1. Vink R, Mclntosh TK, Demediuk P, Weiner MW, Faden AI:
Decline in intracellular free magnesium concentration is associated with irreversible tissue injury following brain trauma.
J Biol Chem 263: 757-761, 1988 2. Vink R, Heath DL, Mclntosh TK: Acute and prolonged alterations in brain free magnesium following fluid percussion induced brain trauma in rats. J Nurochem 66:2477-2483, 3. Heath DL, Vink R: Brain intracellular free magnesium concentration declines following impact-acceleration induced brain injury in rats. Neurosci Res Commun 18: 163-168, 1996 4. Heath DL, Vink R: Traumatic brain axonal injury produces sustained decline in intracellular free magnesium-concentration.
Brain Research 738: 150-153, 1996 5. Mclntosh TK, Faden AI, Yamakami I, Vink R: Magnesium deficiency exacerbates and pretreatment improves outcome following traumatic brain injury in rats: 3'P magnetic resonance l0 spectroscopy and behavioural studies. J Neurotrauma 5: 17-31, 1988 6. Vink R, Mclntosh TK: Pharmacological and physiological effects of magnesium on experimental traumatic brain injury.
Magnesium Res 3: 163-169, 1990 7. Heath DL, Vink R: Magnesium sulphate improves neurologic outcome following sever closed head injury in rats.
Neuroscience Letters 228: 175-178, 1997 8. Heath DL, Vink R: Neuroprotective effects of MgS04 and MgC12 in closed head injury: a comparative phosphorus NMR
study. J Neurotrauma 15: 183-189, 1998 9. Heath DL, Vink R: Delayed therapy with magnesium up to 24 hours following traumatic brain injury improves motor outcome.
J Neurosurg 90: 504-509, 1999 10. Heath DL, Vink R: Optimisation of magnesium therapy following sever diffuse axonal brain injury in rats. J Pharmacol Exp Ther 288: 131 1-1316, 1999 11. Feickert HG, Drommer S, Heyer R: Severe head injury in children: impact of risk factors. J Trauma 47: 33-38, 12. Moskowitz MA: The neurobiology of vascular head pain.
Ann Neurol16: 157-168, 1984 13. Ferrari MD: Migraine. Lancet 351: 1043-1052, 1998 14. Altura BT, Altura BM: The role of magnesium in etiology of strokes and cerebrovasospasm. Magnesium 1 : 277-291, 1982 15. Farago M, Szabo C, Dora E, Horvath I, Kovach AGB:
Contractile and endothelium-dependant dilatory_ responses of cerebral arteries at various extracellular magnesium concentration. J Cereb Blood Flow Metab 1 1 : 161-1 64, 1991 16. Kemp PA, Gardiner SM, March JE, Rubin PC, Bennett T:Assessment of the effects of endothelia-1 and magnesium l0 sulphate on regional blood flows in conscious rats, by the colour microsphere reference technique. Br J Pharmacol 126:
621-626, 1999 17. Morril MA, Gupta RI<, Kostellow AB, Gy M, Zhang A, Altura BT, Altura BM: Mg2 + modulates membrane sphingolipid and lipid second messenger levels in vascular smooth muscle cells.
FEBS Lett 167-171, 1998 ~
E
c4 C
-o t n.
L
L U
n N t N
l- ~U '-' cB i N
C (n O n L , N ~
o ~ ~_ ~ ~ u~
J U ~ s O
U _ , C p Q N
~J1O
N p L
M ~ N L ., L ..-1 ~ N 'p v ~ ' ~ COp >, C 7, '~ ~U ~ N
w-. C L O r C o ~ y ~ C u) E
C _ 0 N N Z ~ Q 0 o B , .=, N ' C N O ~ = ~' O N >, C N
T
O O O O .t..C ~ .C N ~ , Q. U p fl. .-. ~ '~ C
'Q v ~ Q ~ a ~ a~ E a7 ~ 'C N
'_d'fCO 7, Z, C1 r T C Q r d i N O
N C O C a O
, p , O T CL r ~ p , ~ 7 _ x O r ~ Q. O ~' O
N ' L N N ~ ~ C v L ~ O J Q ~ _ ~ N v ~ ~' i~
O E p 7, v '; ~E ~ ' N ~ f~
E C - N ~ Z
C - O- CC O _ >, c0 r iv ~ >' M
a c ~ >, ~ ~ C ~. X ~ :.
L >' p N p u7 >, .C O T
Z C C ~ C E t N ~ O = Q O
X N O T ~ O Q p ~ ~. ~ t ~ O. ~, c%~' o r s 7, N fn t N O ~ >, ~ fl.z N N p 7, ...~ L ~ - L p ~ L ~, X
O N O .-.C N ~ H _O, d N
N O .- O t C ~ O ~ ' ~ u) O Z ~ ~ C ~
_c~0 '''~ O ~ ~ N ~ N
E ~, ' O ' tf7' O ~ O p >, C N
7, , >' J ~ L C ~ p Z C r p X E O 'p N E E
7,O ..~~.p L ~ ~ ~ ~ ->~~O
O D ~ p "'.'~ S O
N ~' ' ~-'p U i ~ ~.;~ ~ ~, O
~n E O X v p ~ ~ ~ M C C
s O ~ ~ N cC ~ N cp Z ~! C N ,_..,j, N i ~ Q i U w , r ~ ~ ~ x ~ Z ~ L Z d ~ L , ~ O Q' H M
T 'Ov N .Q M C ~ O O
M yr _>,Q' O _cC n rj ~ v O p ' ~
N M ~ N ~ Q ~ "'' ~ ~
C ' N V ~ -~ C t~ _~O_ J M
~ ~ 'O ~ 'O U ~ r V ~ U ~ M ' CC C ~ Q -C 7, ~
M ~ ~ (n N O O N ~ N (!~iv ~ ~ M ~ N ~ M d a U a N U
iv N ' ~ N N
N fn ~ ~ d Q ~
M ~ ~ M r Z ~r ~
C
Q
O
O
O U M tn~' N O r U t0 N ~hO~ I~ ~ r M O I~ O O
O 0 ct LIJ t~ ~ M ~ ~0 p r N ~ ~ ~ r O (O O
O N r O
d O O o0 N N a0 O M N M N
U U an ~ J
U U U I~tC~ C7 C9 C'~Z J J J J
i4 , z ,"
' o _ ~
s >, J
T
O ~ ~ V :Q >, c c _(p ~
, COU ~, N U ca r~ ~ n , C r T O I~
Z - N
D O 7, O ~ C r t fl.~ Q ~ L N
r n = 1 N
O O ~ p ~ , a . (D
.C ~ U ~ ~ p ~ O r , CO U E ~ ~ ~ ~ tn _O et _~ , i , O O U_ r , n 7, ~ ~ C 'O~O
m .
->, N , ' _ L ~ V N
O O .
T ~, Z .C ~ ' ' .C r C ~ c4 Q N
~ = ~ T O O ~, ~
j, ~
7 t _ ~ ~,O M r te r ~- c ... ~ .ca _>, ..
o E J E _ E z ~ O ~ O T p -p 7 ~' L =
, , c M
~ > O t N
T , ~ ~ , O CC
n ' ~ n c M c~7T t ~ C -, ~ M
. n 7, _, n _I n O C ~ ~ M
O_ ~
C .C O O p O O N
C C ~ ~ O ~ n p ~ N
O t0 ~_ C 7, ~ ' C
X Z ~ = U ~ N J O ~ >, OJ r d r 0 ~' p N ' .-, ~ _ ~! = CE
p_ o M w .C ~ ~
-on ~ ' >
, N
', X , T >, C M
U
_ r O , p L ~, ~ ~ ~ ~ ~ "
7 ' ~
c ~ c o X a a c y o 0 a N .E j ~ + ~ N ~- r O J N
. o r ' r , , ~ + E W ~ ~ 1 U n c r d , + 1 c , 'L
t a C .
r L C C ~ M n Q (n CU
7, ~ ' N ~ p >, N N
~' N ~ ~
c N ~ N ~, ~, ~ ca ~
a V ~ ~' , . 1 ~~ V N O
.
o E M ~, c ~. I
~ o s U c J >, o ce c = t ~ ~ ~ O = O ~ ' C O N
Q 7 ~
, n c ca . z Q ~ N
. C , cn 'c . r C 7 ' ~ z C >' , i V O >, p ~, n p x .g o = o >' o c~ o t I~ p >, ~ ~
~ ' ,n p * .c .J .c M o . ~ n n ' , O w-.~ .....i ~ n .. L = Q ~ ~
~ .M. M
r s_ p M N O , t- ..~ H ~
N~. L N ~,M
"
~ X O , ~ ~ M
~ N C ~ ~ O ~ ~ O O
~ * _ N ~ ~ '~~ C p_ ~
o ' ~ '-' ~ I co ca ~n p_' O v~ ~ ~ v ~ p N ~ N C U - n ~
~, CO , ~, C4 t r r =
M O N ~ a7 ' ~"~ n N ~ CV Z ~ "
~ -, ' .~ U .,..U Z i ~ m ~ C r , c 1 N N cU r t c ~ , N N p * >
, , ,_ N ~ s ~ ~ ~ - , , f , U -, ., ~ ~ n ~
.
n N N N , ~ ~ ~ ~ ~ p > C ~ O
c , N s Q"
Z ~ . c , N
a . O U
_ Z N Z ' d _ N O N nJ '=
~ N ~ ~
O s ~ t U
>, - 't?
: ai ~ ai ~ ~ U z ~ n ~ U , s- n _ N >, :o ~ :a - c O a a~'~ N ~ o , ~ n o C N ~ >, ~ ~ O N i. t ' _ Z , ' ~ O
Cvj Z Q n ' C.rj~ V T N
n ~ n ~-' ~-'' ~ U O ~ ~ 0 ~ ~' 'D ~
-' s o C7,N U ~ U e~ OCS i' v ~ iv O a ;o ~ Nr C Q ~ ~ C ~ . l (n s , ~o o N
- M C , C N N ~ N J, . c0 n ~ CC a M fC M ' ~ " L , p ~ ~
O ~ N ~ N t ~ '~ Q' OC N U ~' t ~ .r Q, c Z ~ ~ ~ N ~ . O
O ~ U
p I~'ct, J N N ~
~
V fl r n C N p ~ U r ~ mN
. . _ ~ r ' f- ~ ~ O~ ~ ' ' o -o d a ~ %~ a. ~ ~ ~ m ca T z - ~ t~
o Z
~
J E ~ ~ ~ N M ~ Q ~ v H D J ~ 'O
U 'a N
M
O O O
r O O ~ O '-~~~ M
O N ~ ~ r O ~ O -p O N r o O u7O 'Q 'O M N
p O O O r ~ ~ ~ ~ r ~ :. :~. ~ V~ (O
p M M M Z , ~ ~ ~ ~ T COO r Z Z
~
t0 _ _ < ~ ~ ~ ~ Y p 'n a ~ n n n J J J J ~ ~ d x , L
N
U
m .
o E
s ~ E ca , N N >, .fl E E c L
N Z _ U
, O
'O
r !~ n 'ct E
, ~ ~ L
~ ~ O
c ~ c , .o 47 , C
-p ~ c .L
~1 ~L
.a n 'a .c .
... _~- >, n c >' c :o c c a~ o .c o ' ~ ~ a~
n 'n L ~r :~ o .~ , o t >, Q ~_ M
U S O E 7, d 'd' O s O
~, ~
M ~, N
N O
N C C U 7, O
- ' ' ~. O
. O I N t . ~ 'C N Z U
C
_ f t O C n , N ~' n -O _ >' N
fl-n ~ E N
ca C ' Q ...C = Q E 7, C z L = C N
~
N ~ N O n Z O O C
, '_"
O .C z O , t ~ N
U O p O N N Q. ,~
M
d U m ~ N
' O d U N T
~
O 7 ~ 'p vp ~ ' - ~ ~n E
o Z caE ri o N
O M , " a> Q c% y 0 ~ ~ ~ a cQ: ;
~ N
!
, N Q, p , j ~ N
N >, _ CO T Q N ~ C i N
~.
a N L c 7, O ~
, = ~, O fl. H n ' O.~
C , ~... r N ~ ~ ~ N ~ d , 7, , >, Z N-Q ~ ~ ~ r ~ = t U rM
o r !0 , z M ~ ~ cC ~
~
t H Q , Q ~ U
.
_, , ~ N v ~ U 47 Z
V O O ~ !3 ~ > , L
C7 ~
tn , , ~ ' ~ d ; O ~ ~ z O
Z o o c~ V
U U - ~ ~
Q L ~ . L Q L ~ ~ , ~
.
V ~ V U ~ d V M = a r Q Q
d L d 'a Q O Q
O
I~ (~ r M
U iv c ~ ~ ~ U iv ~
o o c LLI t,1O O op ~ N v N ~ N a0 Q N
~ r ~ ~t J ' ~r N o ~ W m N ~
r ~ c ~ ~ M r ~ o ~ 00 Y
o O
V fn J ~ fn C9 ~ Z C) fn o' Q'cn J Z
I-Z
Claims (20)
1. A formulation comprising a substance P receptor antagonist and a magnesium compound.
2. A formulation as claimed in claim 1, wherein the substance P receptor antagonist is an NK1 receptor antagonist.
3. A formulation as claimed in claim 2, wherein the NK1 receptor antagonist is selected from the group consisting of CGP49823, CP-96,345, CP99,994, CP-122,721, FK88, GR203040, GR205171, GR82334, GR94800, HSP-117, L-703,606 oxalate, L-732,138, L-733060, L-742, 694, L-745,030, L-668,169, LY-303241, LY-303870, LY306740, MEN-11149, MK-869, PD-154075, R-544, RP-67580, RPR100893, Sendide, Spantide II, Spantide III, SR140333, WIN-41,7098, WIN-62,577.
4. A formulation as claimed in claim 1, wherein the substance P receptor antagonist is an NK2 receptor antagonist.
5. A formulation as claimed in claim 4, wherein the substance P receptor antagonist is selected from the group consisting of SR-48968, L-659877, GR103537, MGN-10627, SR144190 and GR94800.
6. A formulation as claimed in claim 1, wherein the substance P receptor antagonist is an NK3 receptor antagonist.
7. A formulation as claimed in claim 6, wherein the substance P receptor antagonist is selected from the group consisting of SR-142,801, R820, R486, SB222200, L758,298 and NKP608.
8. A formulation as claimed in claim 1, wherein the substance P receptor antagonist is N-acetyl L-tryptophan.
9. A formulation as claimed in claim 1, wherein the magnesium compound is selected from the group consisting of magnesium chloride, magnesium sulphate, magnesium oxalate, magnesium gluconate or other non-toxic magnesium salt.
10. The use of a substance P receptor antagonist for treatment of brain, spinal cord and nerve injuries.
11. The use of a formulation comprising a substance P
receptor antagonist and a magnesium compound for treatment of brain, spinal cord and nerve injuries.
receptor antagonist and a magnesium compound for treatment of brain, spinal cord and nerve injuries.
12. The use of a substance P receptor-antagonist for reducing brain barrier permeability and/or reduced vasogenic oedema.
13. The use of a formulation comprising a substance P
receptor antagonist and magnesium compound for reducing brain barrier permeability and/or reduced vasogenic oedema.
receptor antagonist and magnesium compound for reducing brain barrier permeability and/or reduced vasogenic oedema.
14. The use according to claim 10 or 11, wherein the injuries are caused by laceration, tearing, stretching or compression of nerve fibres.
15. The use according to claim 10, wherein the substance p receptor antagonist i.v. dose varies from 24.6mg/kg to 240.6mg/kg or higher.
16. The use according to claim 11, wherein the i.v.
dose of the magnesium compound ranges from 16mg/kg to 60mg/kg.
dose of the magnesium compound ranges from 16mg/kg to 60mg/kg.
17. The use according to claim 11, wherein an intramuscular dose of magnesium compound ranges from 45mg/kg to 90mg/kg.
18. The use according to claim 11, wherein the dosage of magnesium compound is sufficient to increase free magnesium concentration in the blood to approximately 1.0mM.
19. A formulation as claimed in claim 1 substantially as herein described with reference to the Experimental Section.
20. The use of a substance P receptor antagonist as claimed in claim 10 substantially as herein described with reference to the Experimental Section.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPQ5146 | 2000-01-18 | ||
AUPQ5146A AUPQ514600A0 (en) | 2000-01-18 | 2000-01-18 | Brain injury treatment |
PCT/AU2001/000046 WO2001052844A1 (en) | 2000-01-18 | 2001-01-18 | Brain, spinal and nerve injury treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2397723A1 CA2397723A1 (en) | 2001-07-26 |
CA2397723C true CA2397723C (en) | 2010-08-31 |
Family
ID=3819274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2397723A Expired - Fee Related CA2397723C (en) | 2000-01-18 | 2001-01-18 | Brain, spinal and nerve injury treatment |
Country Status (21)
Country | Link |
---|---|
US (5) | US6841551B2 (en) |
EP (1) | EP1261335B1 (en) |
JP (1) | JP4794794B2 (en) |
KR (1) | KR100780119B1 (en) |
CN (1) | CN1261095C (en) |
AU (2) | AUPQ514600A0 (en) |
BR (1) | BR0107695A (en) |
CA (1) | CA2397723C (en) |
CZ (1) | CZ20022804A3 (en) |
DE (1) | DE60139244D1 (en) |
HK (1) | HK1054872A1 (en) |
HR (1) | HRP20020593B1 (en) |
HU (1) | HUP0301920A3 (en) |
IL (2) | IL150548A0 (en) |
MX (1) | MXPA02007004A (en) |
NO (1) | NO329320B1 (en) |
NZ (2) | NZ519990A (en) |
RU (1) | RU2276996C2 (en) |
WO (1) | WO2001052844A1 (en) |
YU (1) | YU54702A (en) |
ZA (1) | ZA200205715B (en) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ514600A0 (en) | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
MXPA05008097A (en) | 2003-01-28 | 2006-02-08 | Microbia Inc | Methods and compositions for the treatment of gastrointestinal disorders. |
GB0410215D0 (en) * | 2004-05-07 | 2004-06-09 | Lescroart Pol | Nerve damage |
AU2005286733B2 (en) * | 2004-09-23 | 2009-11-05 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
US20080045610A1 (en) * | 2004-09-23 | 2008-02-21 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
BRPI0606187A2 (en) | 2005-02-25 | 2009-06-09 | Hoffmann La Roche | tablets with improved drug substance dispersibility |
WO2006110118A1 (en) * | 2005-04-15 | 2006-10-19 | Victor Pavlovich Kutnyak | Cytoprotection preparation |
US8185176B2 (en) | 2005-04-26 | 2012-05-22 | Novadaq Technologies, Inc. | Method and apparatus for vasculature visualization with applications in neurosurgery and neurology |
US20060239921A1 (en) * | 2005-04-26 | 2006-10-26 | Novadaq Technologies Inc. | Real time vascular imaging during solid organ transplant |
CA2618443A1 (en) * | 2005-08-10 | 2007-02-15 | Novadaq Technologies, Inc. | Intra-operative head & neck nerve mapping |
US20070122344A1 (en) * | 2005-09-02 | 2007-05-31 | University Of Rochester Medical Center Office Of Technology Transfer | Intraoperative determination of nerve location |
WO2007062060A2 (en) * | 2005-11-22 | 2007-05-31 | Ted Reid | Methods and compositions using substance p to promote wound healing |
US8945623B2 (en) * | 2006-05-03 | 2015-02-03 | Warsaw Orthopedic, Inc. | Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use |
US20080161744A1 (en) * | 2006-09-07 | 2008-07-03 | University Of Rochester Medical Center | Pre-And Intra-Operative Localization of Penile Sentinel Nodes |
US20080241121A1 (en) * | 2007-04-02 | 2008-10-02 | Daniela Salvemini | Inhibitors of the ceramide metabolic pathway as adjuncts to opiates for pain |
US20100086543A1 (en) * | 2007-04-02 | 2010-04-08 | Saint Louis University | Compositions and methods for treating conditions associated with ceramide biosynthesis |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
CA2688161C (en) | 2007-06-04 | 2020-10-20 | Kunwar Shailubhai | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
KR20100055430A (en) * | 2007-07-19 | 2010-05-26 | 애들레이드 리서치 앤드 이노베이션 피티와이 리미티드 | Method for reducing intracranial pressure |
US8406860B2 (en) | 2008-01-25 | 2013-03-26 | Novadaq Technologies Inc. | Method for evaluating blush in myocardial tissue |
US10219742B2 (en) | 2008-04-14 | 2019-03-05 | Novadaq Technologies ULC | Locating and analyzing perforator flaps for plastic and reconstructive surgery |
US20090263507A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Biological markers and response to treatment for pain, inflammation, neuronal or vascular injury and methods of use |
ES2671710T3 (en) | 2008-05-02 | 2018-06-08 | Novadaq Technologies ULC | Methods for the production and use of erythrocytes loaded with substances for the observation and treatment of microvascular hemodynamics |
ES2522968T3 (en) | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
ES2624828T3 (en) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others |
WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
MX345283B (en) | 2008-12-31 | 2017-01-24 | Ardelyx Inc | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders. |
US8852566B2 (en) * | 2009-03-26 | 2014-10-07 | Warsaw Orthopedic, Inc. | Compositions and methods for preferential distribution of active agents to injury sites |
US10492671B2 (en) | 2009-05-08 | 2019-12-03 | Novadaq Technologies ULC | Near infra red fluorescence imaging for visualization of blood vessels during endoscopic harvest |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
WO2012074043A1 (en) * | 2010-12-03 | 2012-06-07 | 国立大学法人 岡山大学 | Therapeutic agent for traumatic neurological disorders |
WO2012125020A1 (en) * | 2011-03-14 | 2012-09-20 | N.V. Nutricia | Method for treating neurotrauma |
CA2914778A1 (en) | 2012-06-21 | 2013-12-27 | Novadaq Technologies Inc. | Quantification and analysis of angiography and perfusion |
CA2880338A1 (en) | 2012-08-21 | 2014-02-27 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
US9486494B2 (en) | 2013-03-15 | 2016-11-08 | Synergy Pharmaceuticals, Inc. | Compositions useful for the treatment of gastrointestinal disorders |
KR20230132619A (en) | 2013-04-12 | 2023-09-15 | 알데릭스, 인코포레이티드 | Nhe3-binding compounds and methods for inhibiting phosphate transport |
JP6606491B2 (en) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | Ultra high purity agonist of guanylate cyclase C, method for producing and using the same |
BR112015032534B1 (en) * | 2013-07-02 | 2020-03-03 | Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) | USE OF PHARMACEUTICALLY ACCEPTED COMPOUNDS OR SALT OR SOLVATE THEREOF |
EP3016659A4 (en) * | 2013-07-02 | 2017-03-15 | Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) | Method for preventing and/or treating chronic traumatic encephalopathy-iii |
MX370176B (en) * | 2013-07-02 | 2019-12-04 | Eustralis Pharmaceuticals Ltd Trading As Pressura Neuro | Method for preventing and/or treating chronic traumatic encephalopathy-i. |
US20160129007A1 (en) * | 2013-07-02 | 2016-05-12 | Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) | Method for Preventing and/or Treating Chronic Traumatic Encephalopathy - IV |
CA2963987A1 (en) | 2014-09-29 | 2016-04-07 | Novadaq Technologies Inc. | Imaging a target fluorophore in a biological material in the presence of autofluorescence |
KR102012880B1 (en) | 2014-10-09 | 2019-08-22 | 노바다크 테크놀러지즈 유엘씨 | Quantification of absolute blood flow in tissue using fluorescence-mediated photoplethysmography |
JP7292207B2 (en) | 2017-01-09 | 2023-06-16 | アルデリックス, インコーポレイテッド | Compounds Useful for Treating Gastrointestinal Disorders |
CA3049679A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Inhibitors of nhe-mediated antiport |
US11140305B2 (en) | 2017-02-10 | 2021-10-05 | Stryker European Operations Limited | Open-field handheld fluorescence imaging systems and methods |
KR20220050956A (en) * | 2019-08-23 | 2022-04-25 | 유스트랄리스 파마슈티칼스 리미티드 (트레이딩 애즈 프레스수라 뉴로) | Methods of treatment and uses thereof |
WO2021202286A1 (en) * | 2020-03-30 | 2021-10-07 | Dignify Therapeutics, Llc | Compositions and methods for treating autonomic dysreflexia |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4481139A (en) * | 1983-04-13 | 1984-11-06 | Board Of Regents, The University Of Texas System | Peptide antagonists of substance P |
US4985896A (en) * | 1985-03-29 | 1991-01-15 | Canon Kabushiki Kaisha | Laser driving device |
US4981744A (en) * | 1990-04-24 | 1991-01-01 | Swank Michael W | Non-planar expandable honeycomb structure |
PT655055E (en) * | 1992-08-13 | 2001-03-30 | Warner Lambert Co | ANTAGONISTS OF TAQUIQUININ |
US5610165A (en) | 1994-02-17 | 1997-03-11 | Merck & Co., Inc. | N-acylpiperidine tachykinin antagonists |
US5744482A (en) * | 1994-10-05 | 1998-04-28 | Eli Lilly And Company | Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine |
US5998444A (en) * | 1995-10-24 | 1999-12-07 | Zeneca Ltd. | Piperidinyl compounds as NK1 or NK2 antagonists |
IL116249A (en) * | 1994-12-12 | 2003-07-06 | Pfizer | Nk-1 receptor antagonists for the treatment of neuronal damage and stroke |
WO1996024353A1 (en) * | 1995-02-10 | 1996-08-15 | Eli Lilly And Company | Methods of treating or preventing psychiatric disorders |
US5795894A (en) * | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
US5990125A (en) | 1996-01-19 | 1999-11-23 | Pfizer Inc. | NK-1 receptor antagonists for the treatment of cancer |
WO1997038701A1 (en) * | 1996-04-12 | 1997-10-23 | Neotech Medical Innovations In | Composition and method for the treatment of premenstrual syndrome |
US5977104A (en) * | 1996-12-02 | 1999-11-02 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating bipolar disorders |
AU749976B2 (en) * | 1997-08-28 | 2002-07-04 | Merck & Co., Inc. | Method for treating premenstrual or late luteal phase syndrome |
GB9812662D0 (en) * | 1998-06-11 | 1998-08-12 | Merck Sharp & Dohme | Therapeutic use |
CZ20013047A3 (en) | 1999-02-24 | 2002-02-13 | F. Hoffmann-La Roche Ag | 3-Phenylpyridine derivatives and their use as antagonist of NK-1 receptors |
JP4070957B2 (en) | 1999-02-24 | 2008-04-02 | エフ.ホフマン−ラ ロシュ アーゲー | Phenyl and pyridinyl derivatives |
ES2226622T3 (en) | 1999-02-24 | 2005-04-01 | F. Hoffmann-La Roche Ag | DERIVATIVES OF 4-PHENYL PIRIDINE AND ITS EMPLOYMENT AS ANTAGONIST OF THE NK-1 RECEIVER. |
US6291465B1 (en) | 1999-03-09 | 2001-09-18 | Hoffmann-La Roche Inc. | Biphenyl derivatives |
US6274588B1 (en) | 1999-05-31 | 2001-08-14 | Hoffmann-La Roche Inc. | 4-phenyl-pyrimidine derivatives |
JO2308B1 (en) | 1999-05-31 | 2005-09-12 | اف. هوفمان- لاروش أيه جي | 5-phenyl purinidine derivatives |
GB9923748D0 (en) | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
AUPQ514600A0 (en) | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
US6479433B1 (en) | 2000-10-02 | 2002-11-12 | Smithers-Oasis Company | Polyurethane foam composites for grower applications and related methods |
-
2000
- 2000-01-18 AU AUPQ5146A patent/AUPQ514600A0/en not_active Abandoned
-
2001
- 2001-01-18 AU AU26560/01A patent/AU782799B2/en not_active Expired
- 2001-01-18 US US10/181,323 patent/US6841551B2/en not_active Expired - Fee Related
- 2001-01-18 CA CA2397723A patent/CA2397723C/en not_active Expired - Fee Related
- 2001-01-18 DE DE60139244T patent/DE60139244D1/en not_active Expired - Fee Related
- 2001-01-18 RU RU2002121640/15A patent/RU2276996C2/en not_active IP Right Cessation
- 2001-01-18 NZ NZ519990A patent/NZ519990A/en not_active IP Right Cessation
- 2001-01-18 NZ NZ534278A patent/NZ534278A/en not_active IP Right Cessation
- 2001-01-18 CN CNB018037208A patent/CN1261095C/en not_active Expired - Fee Related
- 2001-01-18 HU HU0301920A patent/HUP0301920A3/en unknown
- 2001-01-18 JP JP2001552892A patent/JP4794794B2/en not_active Expired - Fee Related
- 2001-01-18 WO PCT/AU2001/000046 patent/WO2001052844A1/en active IP Right Grant
- 2001-01-18 BR BR0107695-7A patent/BR0107695A/en not_active IP Right Cessation
- 2001-01-18 CZ CZ20022804A patent/CZ20022804A3/en unknown
- 2001-01-18 MX MXPA02007004A patent/MXPA02007004A/en active IP Right Grant
- 2001-01-18 YU YU54702A patent/YU54702A/en unknown
- 2001-01-18 KR KR1020027009218A patent/KR100780119B1/en not_active IP Right Cessation
- 2001-01-18 EP EP01901048A patent/EP1261335B1/en not_active Expired - Lifetime
- 2001-01-18 IL IL15054801A patent/IL150548A0/en unknown
-
2002
- 2002-07-02 IL IL150548A patent/IL150548A/en not_active IP Right Cessation
- 2002-07-16 HR HR20020593A patent/HRP20020593B1/en not_active IP Right Cessation
- 2002-07-17 NO NO20023423A patent/NO329320B1/en not_active IP Right Cessation
- 2002-07-17 ZA ZA200205715A patent/ZA200205715B/en unknown
-
2003
- 2003-10-14 HK HK03107353A patent/HK1054872A1/en not_active IP Right Cessation
-
2004
- 2004-12-21 US US11/017,978 patent/US20050107380A1/en not_active Abandoned
-
2009
- 2009-06-01 US US12/475,627 patent/US9186404B2/en not_active Expired - Lifetime
-
2015
- 2015-10-13 US US14/882,084 patent/US20160030474A1/en not_active Abandoned
-
2017
- 2017-09-25 US US15/714,819 patent/US10201568B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2397723C (en) | Brain, spinal and nerve injury treatment | |
Pollock et al. | The use of arthroscopy in the treatment of resistant frozen shoulder | |
RU2244558C2 (en) | Anesthetic composition comprising nmda-antagonist and alpha-2-adrenergic agonist | |
Klamt et al. | Postoperative analgesic effect of intrathecal neostigmine and its influence on spinal anaesthesia | |
Gatt et al. | Preemptive analgesia: its role and efficacy in anterior cruciate ligament reconstruction | |
Jönsson et al. | Intravenous indomethacin and oxycone‐papaverine in the treatment of acute renal colic. A double‐blind study | |
Yamada et al. | Comparison of conservative and operative treatments of massive rotator cuff tears | |
TAMAI et al. | Intratendinous Tear of the Supraspinatus Tendon Exhibiting Winging of the Scapula: A Case Report. | |
PL203468B1 (en) | Preparation for venous or intramammary treatment of brain, spinal cord and nerve damage | |
Shenoi | Chemical warfare agents | |
Barrett et al. | Quinine ocular toxicity: treatment of blindness using therapy for vasospasm | |
RU2154481C2 (en) | Method of treatment of wrist phlegmon | |
Al Dhaheri | Effect of Lead on Flexor Muscle Contraction and Photochemically-Induced Platelet Aggregation in Pial Microcirculation of the Mouse | |
Cooke | MINERS'NYSTAGMUS | |
Pulley | Medical Management of Chemical Warfare Agents | |
Jivegård et al. | Loperamide inhibits gallbladder inflammatory fluid secretion in experimental cholecystitis | |
Rani et al. | Enhanced contractility of the rat stomach during suppression of angiotensin converting enzyme by captopril in vitro. | |
Darnell et al. | Convulsant versus typical barbiturates: effects on locomotor activity | |
WELLER | THE PATHOLOGY OF GASSING. | |
Gögler et al. | Shock and Trauma | |
Kaplan et al. | Transient Blindness during Pralidoxime Administration for Organophosphate Toxicity | |
Day | chiefly in Illinois, Massachusetts, New Jersey, New | |
Martin et al. | Severe muscle injury after social drug use | |
Sheng-de | Burns of Special Causes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20140120 |